InterventionsHumans

Changes in Clinical Measures in U.S. Adults with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) Who Received Once-Weekly (OW) Semaglutide

ADA Scientific Sessions 2025 Abstract

The paper

James J. Amamoo, Yan Wang, Hongjiao Liu,

Manasvi Sundar, Yan Song, Lin Xie, Sherif J. Mehanna, Joshua Noone, Caroline Swift,

Matthew R. Weir

Los Angeles

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Poster 838-P

doi.org/10.2337/db25-838-p

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026